Jim C. Oates

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2009 · 1.4K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +13

Urine Biomarkers Predict the Cause of Glomerular Disease

Sanju A. Varghese, T. Brian Powell, Milos N. Budisavljevic et al. · Journal of the American Society of Nephrology · 2007 · 221 citations · Full text

Life Sciences, Biochemistry, Nephrology +17

Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases

Leslie J. Crofford, Jim C. Oates, W. Joseph McCune et al. · Arthritis & Rheumatism · 2000 · 153 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Upregulation of xCT by KSHV-Encoded microRNAs Facilitates KSHV Dissemination and Persistence in an Environment of Oxidative Stress

Zhiqiang Qin, Eduardo Freitas, Roger J. Sullivan et al. · PLoS Pathogens · 2010 · 115 citations · Full text

Medicine, Infectious Diseases, Molecular Biology +17

Rheumatology Informatics System for Effectiveness: A National Informatics‐Enabled Registry for Quality Improvement

Jinoos Yazdany, Nick Bansback, Megan E. B. Clowse et al. · Arthritis Care & Research · 2016 · 108 citations · Full text

Computing, Biomedical Informatics, Health Informatics +14